Statins for the primary prevention of cardiovascular disease
about
Statin treatment increases lifespan and improves cardiac health in Drosophila by decreasing specific protein prenylationFixed-dose combination therapy for the prevention of cardiovascular diseaseGeneral health checks in adults for reducing morbidity and mortality from diseasePerioperative statin therapy for improving outcomes during and after noncardiac vascular surgeryStatins for the primary prevention of cardiovascular diseaseUnresolved questions in rheumatology: motion for debate: the data support evidence-based management recommendations for cardiovascular disease in rheumatoid arthritisCardiovascular riskLipid-lowering therapy: who can benefit?Statins, cognition, and dementia—systematic review and methodological commentaryA point-by-point response to recent arguments against the use of statins in primary prevention: this statement is endorsed by the American Society for Preventive CardiologyStatins in the primary and secondary prevention of cardiovascular disease in women: facts and mythsPrimary prevention with statins in cardiovascular diseases: A Saudi Arabian perspectivePatient-accessible tool for shared decision making in cardiovascular primary prevention: balancing longevity benefits against medication disutility.Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trialsThe Oregon experiment--effects of Medicaid on clinical outcomesStatin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting systemPersonalized prediction of lifetime benefits with statin therapy for asymptomatic individuals: a modeling studyLong-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage studyOSAS and metabolic diseases: Round Table, 99(th) SIO National Congress, Bari 2012.Observational data for comparative effectiveness research: an emulation of randomised trials of statins and primary prevention of coronary heart disease.Providing clinicians with a patient's 10-year cardiovascular risk improves their statin prescribing: a true experiment using clinical vignettes.Statin use in adults at high risk of cardiovascular disease mortality: cross-sectional analysis of baseline data from The Irish Longitudinal Study on Ageing (TILDA).Algorithms to Identify Statin Intolerance in Medicare Administrative Claim Data.Cardiovascular risk and statin use in the United StatesFactors influencing dyslipidemia in statin-treated patients in Lebanon and Jordan: results of the Dyslipidemia International StudyHigher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases.Screening strategies for cardiovascular disease in asymptomatic adults.Pharmacological management of non-alcoholic fatty liver disease: Atorvastatin versus pentoxifylline.Atherosclerotic Cardiovascular Disease Risk and Evidence-based Management of Cholesterol.The A4 study: stopping AD before symptoms begin?Long-term atorvastatin treatment leads to alterations in behavior, cognition, and hippocampal biochemistry.Are investments in disease prevention complements? The case of statins and health behaviorsContribution of individual risk factor changes to reductions in population absolute cardiovascular risk.The impact of the time of drug administration on the effectiveness of combined treatment of hypercholesterolemia with Rosuvastatin and Ezetimibe (RosEze): study protocol for a randomized controlled trial.Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.Statins and the risk of type 2 diabetes mellitus: cohort study using the UK clinical practice pesearch datalinkUse of medical services and medicines attributable to diabetes in Sub-Saharan Africa.Significance of a positive family history for coronary heart disease in patients with a zero coronary artery calcium score (from the Multi-Ethnic Study of Atherosclerosis).The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.Prediction of cardiovascular risk using Framingham, ASSIGN and QRISK2: how well do they predict individual rather than population risk?
P2860
Q21090893-DDB98D11-B9DD-46BE-8832-CC5F0A1D2FD1Q24198070-C54353A4-95B7-46C1-AE11-D33DD905E84AQ24198193-9EF85369-EAB0-4F8D-8708-022BA55176C2Q24201360-C47F6804-8581-4105-8E96-B2CBA3D4654AQ24201513-7A5FF33F-7EEE-49A6-AB3B-50A8DB395BF6Q26822912-CFFFB5BC-3ABF-4DE0-9DF8-EDA9AE4E379DQ26825634-F3103F48-A0F0-4E69-89B3-28DC809059CAQ26827432-151CE1CA-9668-40A6-855E-29589B72467DQ26852778-68D6625A-F397-4E5B-873D-FA1678B1D220Q26866033-0477D3BB-9FD7-434F-AB71-C6EB567694A4Q27000723-B608B34A-5E92-4F87-B6AD-85C5048FFB2BQ27002928-11F2BED7-1B48-47B0-A9A1-F43D1350516EQ27339134-BAB58AEE-2BE0-47AF-A4DF-A692C74A97DFQ28085282-63434AE8-CD25-4EE0-AE96-FC570D15AD8FQ28289910-33562179-B249-46F6-968E-E4510B1DA5E9Q28478481-88A2FE0A-9A7D-4241-B315-84F47A88F788Q28484624-51858196-551A-4692-9724-64610F406890Q28659664-7AA60EE6-23EE-4988-A550-F20DB0804DB9Q30437409-A1055CB8-1140-4C36-BF6F-DCCA3E6E1566Q30538243-F0293B2A-7355-41DC-B157-12B737867050Q30571866-A0F28840-5634-48AF-97DD-598914ABEC26Q30980069-C7B949A1-5129-4ADE-9F45-628B2BB846CCQ31113251-5A561ED8-0D12-4E00-A8F0-F8C15A7EE8F2Q33599663-7E6FEBCA-87D4-42F8-9DA6-10530FF25AF5Q33630826-F6C998C6-29B5-4469-9D9E-2303733E7786Q33685412-1AD45C3F-EF15-4735-949F-26225F27A0BAQ33704011-F6053A32-3BD3-4B20-ACBB-AFB63FBF1A88Q33723738-5F6D9607-9EBD-4BFE-BEC7-BB4647D2EB1DQ33724722-B5599437-1D10-4C74-961C-F4F814260697Q33725775-B0363A27-0888-4F58-8465-2C0BB2DCAC33Q33761463-18BAB9F5-72F5-4D82-B2D5-F107014D2189Q33777038-87361B3D-45A9-4489-99DC-E4E2CAEAA653Q33790844-B1657926-58B9-45CD-AAD0-46ACEB74CDEDQ33892516-BAEC6D8D-A056-4938-AA4C-38E7BAAE1BE4Q33972551-8DBB658B-3281-48A4-9C0F-BE1F85A5F2CDQ33986300-0A43461E-577C-4465-905F-23FDCE7A9E77Q34172425-BE84CBBF-2035-4B7C-AC46-B15799051723Q34257566-0876F4CD-B4E3-4317-B5D9-6AAD93CC64D1Q34274829-52B2EA4F-E160-4908-8676-E3E0AE635E16Q34277995-16208004-0D75-4656-9379-AFCF9A88B98D
P2860
Statins for the primary prevention of cardiovascular disease
description
2011 nî lūn-bûn
@nan
2011 թուականին հրատարակուած գիտական յօդուած
@hyw
2011 թվականին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Statins for the primary prevention of cardiovascular disease
@ast
Statins for the primary prevention of cardiovascular disease
@en
Statins for the primary prevention of cardiovascular disease
@en-gb
Statins for the primary prevention of cardiovascular disease
@nl
type
label
Statins for the primary prevention of cardiovascular disease
@ast
Statins for the primary prevention of cardiovascular disease
@en
Statins for the primary prevention of cardiovascular disease
@en-gb
Statins for the primary prevention of cardiovascular disease
@nl
prefLabel
Statins for the primary prevention of cardiovascular disease
@ast
Statins for the primary prevention of cardiovascular disease
@en
Statins for the primary prevention of cardiovascular disease
@en-gb
Statins for the primary prevention of cardiovascular disease
@nl
P2093
P2860
P3181
P1476
Statins for the primary prevention of cardiovascular disease
@en
P2093
Fiona Taylor
Juan-Pablo Casas
Margaret Burke
Shah Ebrahim
Theresa Hm Moore
P2860
P304
P3181
P356
10.1002/14651858.CD004816.PUB4
P407
P577
2011-01-01T00:00:00Z